Verve Therapeutics, Inc. Annual Depreciation in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Verve Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from 2019 to 2023.
  • Verve Therapeutics, Inc. Depreciation for the quarter ending June 30, 2024 was $1.67M, a 24.7% increase year-over-year.
  • Verve Therapeutics, Inc. Depreciation for the twelve months ending June 30, 2024 was $6.29M, a 53.2% increase year-over-year.
  • Verve Therapeutics, Inc. annual Depreciation for 2023 was $5.46M, a 94.5% increase from 2022.
  • Verve Therapeutics, Inc. annual Depreciation for 2022 was $2.8M, a 82.7% increase from 2021.
  • Verve Therapeutics, Inc. annual Depreciation for 2021 was $1.54M, a 15.6% increase from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Annual (USD)
Depreciation, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $5.46M +$2.65M +94.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $2.8M +$1.27M +82.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $1.54M +$207K +15.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $1.33M +$1.23M +1228% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 $100K Jan 1, 2019 Dec 31, 2019 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.